PMID- 31490318

OWN - NLM
STAT- Publisher
LR - 20190906
IS - 1531-7048 (Electronic)
IS - 1065-6251 (Linking)
DP - 2019 Sep 3
TI - Allogenic hematopoietic stem cell transplantation in sickle cell disease.
LID - 10.1097/MOH.0000000000000545 [doi]
AB - PURPOSE OF REVIEW: Discussing the currently available HSCT options for Hb SS
patients highlighting advantages and disadvantages of each modality in the
light
of recently published data. RECENT FINDINGS: When MSD is available,
myeloablative
regimen is the preferred approach for otherwise healthy children whereas the
nonmyeloablative (NMA) regimen is of choice for adults as well as children
with
SCD-associated morbidities. Mixed chimerism is common especially with NMA
conditioning and is usually enough for cure. Alternative donor HSCT outcomes
are
progressively improving especially with posttransplant cyclophosphamide for
GVHD
prophylaxis. SUMMARY: Recent studies comparing HSCT and chronic transfusion
in Hb
SS patients increasingly come in favor of HSCT arm. Advances in HSCT field
led to
donor pool expansion and better tolerated regimens. It is easier now to
tailor a
personalized transplantation plan for almost every patient. A successful
management plan should be sufficiently comprehensive addressing patients' and
families' social and psychological concerns to ensure compliance and improve
outcome.
FAU - Galal, Ahmed
AU - Galal A
AD - Division of Hematologic Malignancies and Cellular Therapy, Department of
Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
FAU - Asslan, Mona
AU - Asslan M
AD - Department of Internal Medicine, Faculty of Medicine.
AD - Tanta BMT Unit, Tanta Educational Hospital, Tanta University, Egypt.
LA - eng
PT - Journal Article
DEP - 20190903
PL - United States
TA - Curr Opin Hematol
JT - Current opinion in hematology
JID - 9430802
SB - IM
EDAT- 2019/09/07 06:00
MHDA- 2019/09/07 06:00
CRDT- 2019/09/07 06:00
PHST- 2019/09/07 06:00 [entrez]
PHST- 2019/09/07 06:00 [pubmed]
PHST- 2019/09/07 06:00 [medline]
AID - 10.1097/MOH.0000000000000545 [doi]
PST - aheadofprint
SO - Curr Opin Hematol. 2019 Sep 3. doi: 10.1097/MOH.0000000000000545.